Newsroom

WALTHAM, MA. November 4, 2024 - Paragonix Technologies, a pioneer in organ transplant technologies and organ procurement services, announces today its BAROguard® System has been recognized as one of TIME’s Best Inventions of 2024 in the medical care category.

Tampa General Hospital (TGH) Transplant Institute successfully transplants donor pancreas in a transplant recipient utilizing next-generation preservation technology

Chapel Hill, NC – October 29, 2024 – Paragonix Technologies, Inc., a leader in organ preservation technology, and HonorBridge, North Carolina’s largest organ donation and tissue recovery organization, are proud to announce the successful transplantation of a donor liver to Tampa General Hospital using Paragonix’s state-of-the-art LIVERguard® technology.

WALTHAM, MA. October 28, 2024 - Paragonix Technologies, a pioneer in organ transplant technologies and organ procurement services, received US Food and Drug Administration (FDA) 510(k) clearance for its donor kidney preservation system, KidneyVault.

WALTHAM, MA. October 15 , 2024 - Paragonix Technologies, a leading organ transplant company, today announced the first lung transplant case in which a set of pediatric donor lungs were preserved using its BAROguard® Donor Lung Preservation System.

WALTHAM, MA. October 3, 2024 - Paragonix Technologies, a leading organ transplant company, today announces a significant milestone in the expansion of the GUARDIAN-Liver clinical registry, now bolstered by over 500 enrollments. In tandem with this growth, the company has appointed Dr. Kiran Dhanireddy, Vice President and Chief of the Tampa General Hospital (TGH) Transplant Institute, as the study's principal investigator.

WALTHAM, MA. August 29, 2024 - Paragonix Technologies, a leading organ transplant company, announced the launch of a new donor organ courier service in partnership with Nationwide Organ Recovery Transport Alliance (NORA).

WALTHAM, MA. August 22, 2024 - Paragonix Technologies, a leading organ transplant company, announced today that it has entered into a definitive agreement to be acquired by Getinge.

WALTHAM, MA. August 20, 2024 - Paragonix Technologies, a leading organ transplant company, has announced the expansion of its GUARDIAN Registry with the introduction of a new sub-study in the cardiac branch of research. This initiative will further enhance the understanding and management of post-transplant rejection, with a particular focus on molecular diagnostics.

WALTHAM, MA. June 27, 2024 - Paragonix Technologies, a leading organ transplant company, announced today the first liver transplant case in which a pediatric donor liver was preserved using the LIVERguard® Donor Liver Preservation System and successfully transplanted by Dr. Deepak Vikraman at Duke University Hospital in Durham, NC. Launched in 2022, the Paragonix LIVERguard has now been used in over 300 clinical liver transplant cases across the United States, with this case being the first use in a pediatric setting.

WALTHAM, MA. June 27, 2024 - Paragonix Technologies, a leader in organ transplant technology, proudly announces the PancreasPak™Organ Preservation System, the first FDA-cleared device designed to protect and monitor donor pancreases during transportation. Pre-orders for this groundbreaking technology begin on June 27, 2024, with full availability slated for September 1, 2024.

WALTHAM, MA. April 12, 2024 - Paragonix Technologies, Inc., a pioneer in organ transplant technologies and services, announces the annual release of the latest GUARDIAN-Heart Clinical Registry report, shared earlier today at the 44th ISHLT Annual Meeting and Scientific Sessions – one of the largest international conferences focused on advanced treatment for end-stage heart and lung disease.

WALTHAM, MA. April 10, 2024 - Paragonix Technologies, Inc., a pioneer in organ transplant technologies and services, presented impactful clinical data on the use of its Advanced Organ Preservation system, LUNGguard®, in the largest real-world multi-center study presented at the 44th ISHLT Annual Meeting and Scientific Sessions – one of the largest international conferences focused on advanced treatment for end-stage heart and lung disease. The study compares conventional ice storage to the Paragonix LUNGguard system.

WALTHAM, Mass. - Paragonix Technologies, Inc., a pioneer in organ transplant technologies and procurement services, announces the full commercial launch of its next-generation transport device, the BAROguard™ Donor Lung Preservation System. After an overwhelmingly positive response and demand during its limited market release, the technology is now available to transplant centers and Organ Procurement Organizations across the United States.

WALTHAM, MA. March 21, 2024 – Paragonix Technologies, Inc., a pioneer in organ transplant products and services, is honored to announce the forthcoming release of new clinical data supporting the use of controlled hypothermic preservation and clinical services. These presentations compare and analyze post-transplant outcomes of patients, presented by a multi-center panel of clinical investigators representing the GUARDIAN Clinical Registries at the 44th ISHLT Annual Meeting and Scientific Sessions, located at the Prague Congress Center in Prague, Czech Republic from April 10-13, 2024.

WALTHAM, MA. March 12, 2024 – The world's first multi-center report demonstrating a digitally connected preservation system utilizing controlled hypothermic storage that increases transparency of preservation conditions to extend the interval between organ procurement and implantation beyond fifteen hours.

WALTHAM,MA. January 17, 2024 – Paragonix Technologies, a pioneer in organ transplant solutions, is proud to publicly announce the recurrent success of a new, innovative strategy recently developed to minimize the complexities and logistics of placing high-risk donor livers.

WALTHAM, MASSACHUSETTS, January 9, 2024 - Paragonix Technologies,a pioneer in organ transplant solutions, is proud to announce the publication of new groundbreaking data reflecting the clinical impact of its flagship advanced preservation device, the Paragonix SherpaPak Cardiac Transport System (CTS), to protect and monitor donor hearts from extended criteria donors.

WALTHAM, MA. November 28, 2023 – Paragonix Technologies, a pioneer in organ transplant solutions, is proud to announce the launch of a comprehensive network of donor organ procurement, preservation, and transportation services. This expansion includes the establishment of seven strategically located procurement hubs across the United States, designed to optimize coordination and logistics for the transplant community. These hubs, equipped to provide around-the-clock, on-demand support, comprise a team of over 50 distinguished procurement professionals, including certified surgeons and preservationists, all dedicated to advancing the field of organ transplantation.

Waltham,MA. November 17, 2023 - Paragonix Technologies, a pioneer in organ transplant technologies and organ procurement services, has successfully completed the world’s first-in-human case utilizing its newest donor lung preservation technology, the BAROguard™ Donor Lung Preservation System, which received FDA 510(k) clearance in August 2023. -

WALTHAM, MA. October 4, 2023 - Paragonix Technologies, a pioneer in organ transplant solutions, is excited to announce the opening of its new corporate headquarters in Waltham, Massachusetts, marking a significant milestone in its journey to advance organ transplant innovations.

CAMBRIDGE, MASSACHUSETTS, September 19, 2023 - Paragonix Technologies, Inc. achieves a historic milestone in Puerto Rico with the first-ever utilization of its advanced liver preservation technology, the LIVERguard™ Donor Liver Preservation System, which preserved, monitored, and tracked a donor liver throughout its extended trip to a transplant center in Florida.

CAMBRIDGE, MASSACHUSETTS, September 7,2023 – GUARDIAN Registry study of over 500 heart transplant patients published in American Society for Artificial Internal Organs Journal (ASAIO) shows a 67% reduction (p=0.011) in Severe PGD (Primary Graft Dysfunction).

CAMBRIDGE, MA. August 24, 2023 - Paragonix Technologies, a leading organ transplant company, received US Food and Drug Administration (“FDA”) clearance for its next generation donor lung preservation system, BAROguard™. The BAROguard™ System combines Paragonix’s existing advanced hypothermic preservation technology with automated continuous and active airway pressure control, ensuring that an optimal temperature range and a clinically recommended inflation pressure range for donor lungs are maintained throughout the journey from donor to recipient patient.This novel combination of advanced technologies further reinforces the company's ongoing commitment to improve and redefine the standard of care within transplant medicine.

CAMBRIDGE, MA. June 1, 2023 - Paragonix Technologies, a leading organ transplant company, announced today its collaboration with Enduring Hearts, a nonprofit organization dedicated to improving the quality of life for children living with transplanted hearts. Enduring Hearts’ Road to Recovery family program provides pediatric heart transplant families with gas gift cards to help subsidize the costs of burdensome and frequent travel to medical appointments.

From USA TODAY - MAY 23, 2023 Dr. Joseph Rubelowsky felt like he had just robbed a bank. Still in his scrubs, he boarded the Falcon 900 jet plane, sat down and glanced over at the white cooling contraption that held the day’s loot. Strapped to the aircraft floor, it looked like a normal, carry-on suitcase. But what the cooler carried was far from normal – and more precious than money or gold. It was a human heart.

From Boston Herald - MAY 23, 2023 Boston doctors recently performed a historic heart transplant after the life-saving organ was transported 2,506 miles from Alaska to Massachusetts, according to officials. The successful surgery at Massachusetts General Hospital set a new record for the longest distance a donor heart has traveled for transplant surgery via an ice preservation system, the surgical director of MGH’s Heart Transplant Program told the Herald.

Massachusetts General Hospital utilized Paragonix device to transport a donor heart from Alaska to Massachusetts, setting a new record for the longest distance a donor heart has successfully traveled for heart transplant surgery

New GUARDIAN-Heart dataset presented at the 43rd ISHLT Annual Meeting & Scientific Sessions demonstrates that the Paragonix SherpaPak significantly reduced the likelihood of Severe Primary Graft Dysfunction, a life-threatening complication shown to diminish patient survival rates.

In a study assessing high-risk heart donors at the 43rd ISHLT Annual Meeting & Scientific Sessions, GUARDIAN-Heart Registry data indicates a significant reduction in Primary Graft Dysfunction (PGD), a severe post-transplant complication, potentially allowing for an increase in donor hearts available for heart transplant patients.

GUARDIAN-Lung Registry data presented at the 43rd ISHLT Annual Meeting & Scientific Sessions demonstrates statistically significant reduction in 1-year hospital readmission rates (p=0.018) for lung transplant recipients when utilizing the Paragonix LUNGguard Donor Lung Preservation System when compared to traditional ice storage of lungs

CAMBRIDGE, MASSACHUSETTS – March 7, 2023 – Paragonix Technologies, Inc., a leading organ transplant company, today announced that it has secured $24 million in Series B funding, led by Signet Healthcare Partners. This growth investment will bolster Paragonix Technologies’ commercial footprint, including its ongoing extension of clinical service offerings and inventory expansion, and will enable the Company to further advance transplant innovations.

CAMBRIDGE, MASSACHUSETTS – March 6, 2023 – Paragonix Technologies, Inc., a leading organ transplant company, announces new research from a multi-center study on transplant patient outcomes following heart transplant surgery. The study compared the use of the Paragonix SherpaPak® Cardiac Transport System, an FDA-cleared and CE-marked donor heart transport and preservation device, to the use of conventional ice storage for LVAD patients undergoing heart transplantation. Presented at the 2023 American Association of Cardiology Annual Meeting (ACC23) on March 6, the study focused on short term post-transplant outcomes, and utilized data collected by the GUARDIAN-Heart Registry, the world’s largest clinical database specifically dedicated to heart preservation.

Watch the news at FOX 13 – WATCH: Mid-South man recalls receiving heart transplant from Baptist Memorial Hospital

From PSQH – FEBRUARY 10, 2023 The American Society for Artificial Internal Organs recently published new data in its ASAIO Journal from a study comparing hospital costs and clinical outcomes among heart transplant patients. Specifically, the study compared patients who received heart transplants preserved with Paragonix’s SherpaPak versus the common practice of consumer coolers with ice. The study found the SherpaPak method netted an average cost reduction of $26,700 per heart transplantation, due to less time spent in the hospital and less time spent on mechanical circulatory support in the ICU.

CAMBRIDGE, MASSACHUSETTS – February 8, 2023 – Paragonix Technologies, Inc., a leading organ preservation provider, announced today a pioneering lung transplantation case in which donor lungs procured overnight were preserved with the LUNGguard Donor Lung Preservation System, allowing for next day transplant surgery led by Prof. Dr. Laurens Ceulemans at UZ Leuven in Belgium. UZ Leuven Hospital, one of the most innovative and respected transplant centers in Europe, recently completed this landmark case, also marking the first use of the LUNGguard System in a pediatric lung transplant case anywhere in the world.

From Medical Design Briefs – FEBRUARY 1, 2023 The latest developments in medical technologies — including the use of artificial intelligence, telehealth, integrated technologies, and data intelligence — are geared toward improving patient engagement. Clinical precision medicine, which includes leveraging the individual patient’s data, connecting the patient with their provider, and then leveraging AI or machine learning in a way that will help drive behavior change specific to the individual is one example of how this trend is taking shape. In addition, next-generation telehealth platforms can increase overall satisfaction through seamless integration with other patient engagement tools, automation of administrative workflows, and dedication to continuous updates.

From Hawaii Public Radio – December 15, 2022 – New technology is helping Legacy of Life Hawai‘i give the gift of life to people outside of our islands. The nonprofit has teamed with Paragonix Technologies to use a new kind of cooling device to transport organs for transplant to the mainland. It maintains the organs at a temperature between 4 and 9 degrees Fahrenheit, unlike traditional methods of using a cooler and ice, which aren’t able to regulate temperature.

LITTLE ROCK, Ark. -December 14, 2022 – Baptist Health has a new way to transport donor hearts and give transplant patients a better chance at life. The SherpaPak is the latest way doctors will get donor hearts to and from their patients.

From UZ LEUVEN – December 8, 2022 – Advanced Lung Preservation goes global. Belgium-based center UZ Leuven is the first European center to leverage our LUNGguard system to prevent cold injury to donor lungs. Dr. Laurens Ceulemans discusses his team’s experience, and the potential that warmer temperatures enabled by our technology may hold for their center.

From Bostlnno – December 8, 2022 – Each year, BostInno looks back at our coverage from the last 12 months — at launches, funding rounds, new deals and partnerships, awards and more — and tries to identify the startups that are on the verge of something big. Paragonix was selected as one of Boston’s few startups to watch in 2023 by the Boston Business Journal!

An exclusive interview with Lisa Anderson, published by We Are Tech Women.

CAMBRIDGE, MASSACHUSETTS – December 6, 2022 – Paragonix Technologies, Inc., achieves a historic milestone in Hawaii with the first-ever utilization of its advanced lung preservation technology, the Paragonix LUNGguard™ system, which protected, monitored and geo-tracked a pair of donor lungs throughout its lengthy voyage to California. The donor organ recovery was managed by the expert staff of Legacy of Life Hawaii, a nonprofit Organ Procurement Organization (OPO) and the only organization in Hawaii federally designated to recover organs and tissue for transplant. Legacy of Life Hawaii works closely with island hospitals to procure and place donor organs for patients in need.

CAMBRIDGE, MASSACHUSETTS – November 22, 2022 – Paragonix Technologies, Inc., a leader in organ preservation technology and research, has announced the publication of a groundbreaking organ transplant study in the American Society for Artificial Internal Organs (ASAIO) Journal. This new study utilizes real-world clinical data to contrast two preservation methods: the Paragonix SherpaPak® Cardiac Transport System (PGNX), and the historic method of organ transport, ice cold storage (ICE). The study illustrates the favorable post-operative impact that advanced preservation technology may have on hospital costs and patient outcomes after heart transplant procedures.

From Bostlnno – October 31, 2022 -As a complex disease geneticist focused on type I diabetes, Lisa Anderson saw quite a few pancreases come through her lab. She was shocked to find that the organs brought to her at Harvard Medical School were coming in coolers filled with crushed ice.

From Medtech Insights – October 31, 2022 – MedTech Insight recently delved into how VantagePoint Advanced Tracking enables unprecedented monitoring and coordination of logistics.

CAMBRIDGE, MASSACHUSETTS – October 18, 2022 – Paragonix Technologies, Inc., a leader in Advanced Organ Preservation (AOP) technology, has announced the launch of its new VantagePoint™ Organ Tracking Technology to pioneer a new era of continuous oversight and real-time visibility for donor organs in transit. Designed to meet the rising standards of transparency and accountability in donor organ transportation, this technology will improve the digital tracking capabilities provided by the Paragonix App, the free-to-download software paired with all Paragonix Advanced Organ Preservation (AOP) Devices to meet the evolving needs of organ transplant professionals.

CAMBRIDGE, MASSACHUSETTS – August 17, 2022 – Paragonix Technologies, Inc. is announcing a major milestone of preserving over 2,000 donor organs, providing transplant centers Advanced Organ Preservation (AOPT) technology and a nationwide clinical support network. Each of these technologies utilize first-of-its-kind preservation methods and have proven to be a major advancement over the current ice and cooler practice still used today. Paragonix devices combine clinically-proven, stable, hypothermic preservation technology with an extensive clinical support network, supplemented by innovative digital tools for complete control over organ tracking, monitoring, and reporting.1

CAMBRIDGE, MASSACHUSETTS – July 19, 2022 – Paragonix Technologies, the leading hypothermic organ preservation provider, announced today it expanded enrollment in its GUARDIAN series of clinical registries aimed at investigating the impact of organ preservation on clinical outcomes in donor organ transplant.

CAMBRIDGE, MASSACHUSETTS – Paragonix Technologies, Inc., a leading organ preservation provider, announced expanded adoption of their LIVERguard Donor Liver Preservation System at the 2022 American Transplant Congress in Boston, Massachusetts. Since the commercial introduction of the LIVERguard system in January 2022, the advanced donor organ preservation system has been utilized at 8 U.S. transplant centers, including UF Health Shands, one of the largest liver transplant centers in the world. Additionally, Paragonix has been partnering with numerous Organ Procurement Organizations in order to provide more access to this unique hypothermic preservation technology.

CAMBRIDGE, MASSACHUSETTS – Paragonix Technologies, Inc., a leading organ preservation provider, announces today groundbreaking research from a multi-center study on one-year transplant patient outcomes following heart transplant surgery. The study compared the use of the Paragonix SherpaPak Cardiac Transport System, an FDA-cleared and CE-marked donor heart transport and preservation device, to the use of conventional cold storage using ice in the preservation of donor hearts destined for transplantation. Presented at the 2022 Annual Meeting of the International Society for Heart and Lung Transplantation on April 27, the study focused on post-transplant outcomes and survival, and utilized data collected by the GUARDIAN-Heart Registry, the world’s largest clinical database specifically dedicated to heart preservation.

CAMBRIDGE, MASSACHUSETTS – Paragonix Technologies, Inc., a leading organ preservation provider, is presenting new research on a variety of organ preservation, transportation and clinical data collection topics. These include data presentations comparing the impact of different preservation methods based on patient outcomes and transplant survival analysis, at the 2022 ISHLT 42nd Annual Meeting and Scientific Sessions conference held at the Hynes Convention Center in Boston, MA.

From KMTV News Now Omaha OMAHA, Neb. (KMTV) — Looking at him, you might not know Tim Hagen is one in 7.9 billion.

CAMBRIDGE, MASSACHUSETTS – February 8, 2022 – Paragonix Technologies announced the first successful heart transplant at the University of Virginia Medical Center using it’s SherpaPak Cardiac Transport System (CTS). The SherpaPak technology provides a safe and effective way for hearts to be transported during the transplant process.

CAMBRIDGE, MASSACHUSETTS – Feb. 2, 2021 – Paragonix Technologies announces a milestone achievement for its Paragonix LUNGguard™ System as the device safely completed a record distance for donor lung transport from Alaska to North Carolina. The longest case in terms of distance and total ischemic time for the LUNGguard Donor Lung Preservation system was completed by Duke University Hospital, one of the largest organ transplant centers in the world.

CAMBRIDGE, MASSACHUSETTS – January 11, 2022 – Paragonix Technologies, Inc., a leading provider of donor organ preservation and transport systems, announced the first time, combination use of LIVERguard™ and Paragonix SherpaPak® to provide advanced preservation for a heart and liver from the same donor.

CAMBRIDGE, MASSACHUSETTS – January 4, 2022 – Paragonix Technologies, Inc. is announcing the release of the recently developed Paragonix Web Portal, an accessible support platform that connects with the Paragonix App and donor organ preservation devices to provide transplant teams the ability to digitally participate in live sessions or review historical cases and clinical case data. For the first time, Paragonix App users will have access to all historical case information specific to their account, with the ability to access the data in aggregate in order to make decisions on how to optimize their organ procurement procedures and protocols.

From Mass Device – Medical Design & Outsourcing Company collaborates with University of Nebraska to increase organ donor reserve.

CAMBRIDGE, MASSACHUSETTS – Dec. 15, 2021 – Paragonix Technologies, the leading hypothermic cardiothoracic organ preservation provider, announced today the first-in-human clinical use of the only FDA cleared cold storage device for donor livers, the LIVERguard™ Donor Liver Preservation System by Mayo Clinic in Florida, one of the largest Liver Transplant Centers in the United States.

From Medgadget Paragonix Technologies, a leading provider of donor organ preservation and transport systems, recently launched a new donor liver preservation system (LIVERguard) and global liver registry. Medgadget sat down with Lisa Anderson, PhD, for an interview.

CAMBRIDGE, MASSACHUSETTS – December 1, 2021 – Paragonix Technologies, the leading hypothermic donor organ preservation provider, announced the first-in-human clinical use of the investigational NRP-DCD Method by the University of Nebraska Medical Center to recover a donor heart and transport it utilizing the Paragonix SherpaPak® System. This novel method to advance heart transplantation utilizing DCD (donation after circulatory death) donors is an innovative combination of proven techniques developed by the University of Nebraska Medical Center to increase the distance DCD donor organs can travel, thus increasing the potential donor pool.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Paragonix Technologies, Inc. is announcing a major milestone of 1,000 preserved donor heart transports since it began clinical use in 2018, with its flagship product, the Paragonix SherpaPak® Cardiac Transport System (CTS). The Paragonix SherpaPak CTS is the leading FDA cleared and CE marked medical device for heart preservation and transport. Four of the top five largest heart transplant programs in the US and 45 programs globally now trust the Paragonix SherpaPak System to preserve and transport critical donor hearts to their recipient donors. The Paragonix SherpaPak CTS protects donor hearts with its rigid, sterile container and maintains a temperature between 4-8ºC, a temperature range recommended by the International Society of Heart and Lung Transplantation as an optional donor heart preservation condition1. The Paragonix SherpaPak CTS replaces the consumer-grade cooler and ice system that has been used historically - a method that was long overdue for innovation. Wireless connection to a simple app gives organ environment tracking and real-time updates to the transplant team, providing the transplant teams with information critical to this complicated surgery.

From Becker’s Hospital Review “We’re very excited to be the first in Illinois to utilize this technology,” said Edwin McGee Jr., MD, surgical director of heart transplantation and ventricular assist device program at Loyola Medicine. Dr. McGee added that after using this transportation method, there was no wait time for the heart to warm up. The recipient required less medicine to wake up the donor heart, and minimal medication to keep it moving during recovery compared to what’s typically required with the traditional method, Dr. McGee said.

CAMBRIDGE, MASSACHUSETTS – October 28, 2021 – Paragonix Technologies, the leading provider of donor organ preservation and transport systems, announces the clinical and commercial launch of LIVERguard™ Donor Liver Preservation System in both the US and Europe, along with the launch of its clinical global registry, GUARDIAN-LIVER (Global Utilization And Registry Database for Improved preservAtion of doNor LIVERs).

Florida hospital enrolls first patient in the study to further understanding how advanced donor organ preservation impacts pediatric patient outcomes.

Medical Device Network caught up with Paragonix CEO Dr Lisa Anderson to find out more about the development of the device and the implications for the transplant field.

Med-Tech Innovation News spoke to Dr. Lisa Anderson, CEO of Paragonix, about its SherpaPak solution which allows for the safe transportation of organs prior to transplants.

CAMBRIDGE, MASSACHUSETTS – September 15, 2021 – Paragonix Technologies announces the launch of a new collaboration with the University of Nebraska Medical Center on a novel method to advance heart transplantation utilizing DCD (donation after circulatory death) donors. This new method is an innovative combination of proven techniques created to increase the distance DCD donor organs can travel, thus increasing the potential donor pool.

Dr Lisa Anderson is the CEO and co-founder of tech startup Paragonix Technologies. She is one of the inventors of the SherpaPak, a transportation device that enables organ transplantation - specifically hearts. It works by using proprietary thermal cooling to keep hearts at a steady temperature during transport, helping the hearts to travel further than using conventional methods, and therefore expanding donor options.

Keeping organs designated for transplantation cool is vital to ensure procedure success. Medtech Insight spoke to Paragonix’s CEO, Lisa Anderson, to learn more.

Dr. Lisa Anderson, CEO, President and co-founder of Paragonix Technologies, Inc., a company delivering a new standard in organ preservation and transport, discusses a new research study called GUARDIAN-LUNG (Global Utilization And Registry Database for Improved preservAtion of doNor LUNGs) to look at lung preservation and how the way the organ is preserved and transported impact the success of the transplant.

From Healthcare Global News A medical device that uses Bluetooth is making it possible for hearts donated for transplants to travel much further, therefore expanding the donor pool. Dr. Lisa Anderson, CEO of Paragonix, tells us how this works.

Lisa Anderson, CEO of Paragonix Technologies, and Dr. Howard J. Eisen, Transplant Cardiologist at Penn State Health Milton S. Hershey Medical Center., join 'Cheddar Innovates' to discuss how the 'SherpaPak' is being used to transport donor hearts more efficiently.

CAMBRIDGE, MASS. – August 5, 2021 – Paragonix Technologies announces the launch of its new OPTION On-Demand Preservation Services Network in the United States. OPTION is an around-the-clock rapid deployment service designed to better serve the transplant community and improve efficiencies in donor organ procurement and recovery. The first phase of the OPTION program has launched, including the establishment of a nationwide forward deployment of distributed inventory at responsive depots to ensure transplant surgeons have access to advanced hypothermic preservation technologies.

CAMBRIDGE, MASS. – June 29, 2021 – Paragonix Technologies, Inc. today announces the launch of its clinical global registry, GUARDIAN-LUNG (Global Utilization And Registry Database for Improved preservAtion of doNor LUNGs). The GUARDIAN-LUNG study is unlike any lung donation registry as it seeks to evaluate a missing piece of the organ donation process: the impact of methods and technologies used for lung preservation and transportation on the success of transplant surgery.

CAMBRIDGE, MASSACHUSETTS, May 24, 2021- Paragonix Technologies announced a partnership with Southwest Transplant Alliance(STA) to provide advanced organ preservation technology as part of both organization’s ongoing work to save lives through organ donation and transplantation. Under this new partnership, Paragonix will provide the technology, clinical support and education on the advanced preservation capabilities delivered by the Paragonix SherpaPak® Cardiac Transport System.

CAMBRIDGE, MASSACHUSETTS, MARCH 12, 2021 – Paragonix Technologies, Inc. announced today that Lisa Anderson, Ph.D., has been elevated to the role of CEO.

CAMBRIDGE, MASSACHUSETTS, February 22, 2021 – Paragonix Technologies, the leading hypothermic cardiothoracic organ preservation provider, announced today the first-in-man clinical use of the only FDA cleared cold storage device for donor lungs, its LUNGguard™ Donor Lung Preservation System, by Duke University Hospital.

CAMBRIDGE, MASSACHUSETTS, January 6, 2020- Paragonix Technologies, the leading hypothermic cardiothoracic organ preservation provider, announced today the clinical and commercial launch of the LUNGguard™ Donor Lung Preservation System in both the USA and in Europe.

CAMBRIDGE, MASSACHUSETTS, January 4, 2020 — Paragonix Technologies, the leading hypothermic cardiothoracic organ preservation provider, announced today that Bill Edelman, Chief Executive Officer and Chairman of the Board, will present at in the 23rdAnnual Needham Virtual Growth Conference on January 11-15th, 2021 in a series of virtual 1:1 meetings reviewing the company’s rapid international growth to over 500 heart transplant systems shipped, expanding product portfolio to lung and digital products, and projections for 2021.

CAMBRIDGE, MASSACHUSETTS, September 28, 2020- Paragonix Technologies announced that its Paragonix SherpaPak™ Cardiac Transport System (CTS) for donor heart preservation and transport is now being used by Stanford Health Care, the first heart transplant center on the West Coast of the United States to implement the system as standard of care for its heart transplant program.

CAMBRIDGE, MASSACHUSETTS, July 20, 2020- Paragonix Technologies, Inc. today announced that its flagship product, Paragonix SherpaPak™ Cardiac Transport System (CTS), is the recipient of a prestigious international design award: the Red Dot Award.

CAMBRIDGE, MASSACHUSETTS, July 6, 2020- Paragonix Technologies, Inc. announced the presentation of new clinical data at the American Transplant Congress (ATC) on the successful use of the Paragonix SherpaPak™ Cardiac Transport System (CTS) for high-risk donor hearts at the Medical University of Vienna – Allgemeines Krankenhaus Wien (Vienna, Austria), a leading European heart transplant center.

CAMBRIDGE, MASSACHUSETTS, June 22, 2020- Paragonix Technologies, Inc. a commercial stage company and leader in organ preservation and transport technology, today announced that Alexander K. Arrow, MD, CFA has joined its Board of Directors.

CAMBRIDGE, MASSACHUSETTS, June 2, 2020- Paragonix Technologies, Inc. today announced that its clinical global registry, the Global Utilization And Registry Database for Improved Heart Preservation (GUARDIAN), has reached enrollment of over 100 patients that have received a donor heart.

Cambridge, Massachusetts — March 17, 2020 – As the days went by, his heartbeat was slowly fading. His condition was terminal. From home to hospital and from hospital to home. Something was wrong with his heart. If he did not get a transplant soon, the doctors gave him a week to live. Time was running out, and all that was left was hope. The heart finally arrived. It came from a traffic accident involving a young couple.

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Paragonix Technologies, Inc. today announced AdventHealth (Orlando, Florida) has adopted its Paragonix SherpaPak™ Cardiac Transport System (CTS) for the preservation of donor hearts for transplantation. A recent application of this innovative technology permitted the transport and preservation of a donor heart from nearly 1,000 miles away from AdventHealth’s transplant center in Orlando, Florida.

CAMBRIDGE, Mass.–(BUSINESS WIRE)– Paragonix Technologies Inc.today announced clearance of a Pre-Marketing Notification (510(k)) with the US Food and Drug Administration (FDA) for its Donor Lung Preservation System – LUNGguard1,2.

CAMBRIDGE, Mass.–(BUSINESS WIRE)--Paragonix Technologies, Inc. today announced that the first series of pediatric donor hearts preserved and transported using Paragonix SherpaPak Cardiac Transport System occurred at University of Florida Health (UF Health) and Le Bonheur Children’s Hospital (TN). Starting in Q1 2019, Paragonix SherpaPak™ CTS have been shipped with heart connectors covering most aortic diameters, permitting the anchoring of variously sized hearts, including small pediatric hearts, to its proprietary suspension system for improved donor heart transport.

DURHAM, N.C.–(BUSINESS WIRE)-Duke University Hospital has transported its first donor heart using the only commercially available FDA cleared and CE marked system for cold donor heart storage and transport. The Paragonix SherpaPak™ Cardiac Transport System (CTS) was used in a clinical case to safeguard a donor heart prior to it being transplanted into an adult recipient, who is recovering well.

Paragonix Technologies is happy to announce that we will be sponsoring pet therapy at the University of Florida! Pet therapy can go a long way to help patients feel like themselves again, and we are proud to give back to patients.

Paragonix Technologies is immensely proud to sponsor one of the most amazing sporting events of 2019: an expedition of a group of 50 patients and medical professionals to the highest mountain of North Africa, Jebel Toubkal (4200m). What’s so incredible about these patients? They have reached the peak of Jebel Toubkal breathing with new lungs! The international group consisted of lung transplant recipients from Austria, Germany, Hungary, Italy, Greece and Romania.

CAMBRIDGE, Massachusetts & Buenos Aires, Argentina—Paragonix Technologies, Inc. today announced that the Paragonix SherpaPak™ Cardiac Transport System (CTS), the industry’s only FDA cleared and CE marked system for donor heart transport and storage, was used for the first time in South America at the Favaloro Foundation University Hospital. The Paragonix SherpaPak™ CTS safeguards hearts during the journey from donor to recipient patient. The Paragonix system incorporates clinically proven and medically trusted cold preservation techniques in a novel suspension system to provide unprecedented physical and thermal protection. Paragonix SherpaPak™ CTS is the only commercially available FDA cleared and CE marked medical device for donor heart transportation.

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Paragonix Technologies, Inc. today announced that the Paragonix SherpaPak™ Cardiac Transport System (CTS), the industry’s only FDA cleared and CE marked system for donor organ heart transport and storage, will be featured in a clinical presentation at the 2019 American Transplant Congress. The meeting is being held June 1-5, 2019 in Boston.

CAMBRIDGE, Mass.–(BUSINESS WIRE)– Paragonix Technologies Inc., and the Lung Transplant Foundation (LTF) today announced an expansion of their partnership for the development of a series of innovative technologies for improved donor lung preservation.At a joint meeting held during the International Society for Heart and Lung Transplantation (ISHLT) 2019 Annual Meeting in Orlando, FL, The Lung Transplant Foundation reviewed how the 2017 OPTN/UNOS policy covering the distribution of lungs donated for transplant has impacted waitlist removal, logistical burden on organ procurement, distances traveled to retrieve lungs and overall lung retrieval costs. Notably, the updated policy expanded the geographical boundaries for lungs to travel, with first priority offered to patients within a 250-mile radius of the donor’s hospital and then expanding within 575 miles, and then finally across the nation if a matching patient cannot be found. The expanded travel distances results in organs needing to be stored longer, making it imperative that as little damage as possible is done to the organ during transit.

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Paragonix Technologies, Inc. today announced clinical results presented during the Paragonix SherpaPak™ CTS 2019 International Heart Summit held during the International Society for Heart and Lung Transplantation (ISHLT) 2019 Annual Meeting in Orlando, FL. Five U.S. and European Centers shared clinical use experiences of the Paragonix SherpaPak™ Cardiac Transport System (CTS) for the preservation of donor hearts destined for heart transplantation.

CAMBRIDGE, Mass.–(BUSINESS WIRE)– Paragonix Technologies, Inc. today announced the opening of the Global Utilization And Registry Database for Improved heArt preservatioN (“GUARDIAN”) post-market registry, which will assess clinical outcomes when employing the Paragonix SherpaPak™ Cardiac Transport System (CTS) for heart transplantations.

CAMBRIDGE, Mass.–(BUSINESS WIRE)– Paragonix Technologies, Inc. today announced that it will be exhibiting at the International Society for Heart and Lung Transportation (ISHLT) 2019 Annual Meeting, from April 3 to 5 at the Loews Meeting Complex in Orlando, Florida. Paragonix executives will be at booth #409/411 providing hands-on demonstrations of its Paragonix SherpaPak™ Cardiac Transport System (CTS), the industry’s only FDA cleared and CE marked system for donor organ heart transport and storage.